Jennison Associates
TPTX

Jennison Associates’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Jennison Associates’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,787
Closed -$1.18M – 732
2021
Q4 		$1.18M Sell
24,787
-431,043
-95% -$19.3M ﹤0.01% 596
2021
Q3 		$30.3M Sell
455,830
-298,030
-40% -$21.2M 0.02% 301
2021
Q2 		$58.8M Sell
753,860
-105,951
-12% -$7.83M 0.04% 194
2021
Q1 		$81.3M Buy
859,811
+27,215
+3% +$3.24M 0.06% 147
2020
Q4 		$101M Buy
832,596
+200,564
+32% +$22M 0.07% 107
2020
Q3 		$55.2M Sell
632,032
-2,472
-0.4% -$172K 0.04% 166
2020
Q2 		$41M Buy
634,504
+5,756
+0.9% +$332K 0.04% 197
2020
Q1 		$28.1M Buy
628,748
+83,298
+15% +$4.42M 0.03% 211
2019
Q4 		$34M Buy
545,450
+227,258
+71% +$10.8M 0.03% 236
2019
Q3 		$12M Buy
318,192
+81,274
+34% +$3.54M 0.01% 380
2019
Q2 		$9.64M Buy
+236,918
New +$8.45M 0.01% 433

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Jennison Associates's TPTX Position: Q1 2022 in Review

Jennison Associates sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 24,787 shares — an estimated $1.18M sold.

Jennison Associates first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $101M in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Jennison Associates reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 24,787 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.18M.
  • Jennison Associates first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
  • Jennison Associates's Turning Point Therapeutics, Inc. Common Stock position peaked at $101M in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.